UCB initiates long-term study of bimekizumab in active axial spondyloarthritis
UCB Biopharma has initiated a long-term study (NCT04436640) to evaluate the safety, tolerability, and efficacy of bimekizumab in patients with active axial spondyloarthritis, which includes both ankylosing spondylitis and nonradiographic axial spondyloarthritis.